ZB
ZBH
ZBH What Zimmer Biomet Holdings promised, and what happened
Guidance
What management said, and what became of it
25 of 26 judged targets kept · 53 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| ROSA with OptimiZe next-generation kinematic knee robot launch | launching next-generation ROSA (OptimiZe) before the end of 2025 | Jun 2025 | driven by both ROSA with Optimize | Achieved |
| Adjusted diluted EPS | $8.30 to $8.45 | Dec 2025 | we are increasing our adjusted earnings per share expectations for the year to a range of $8.47 to $8.59 and versus our prior guidance of $8.40 to $8.55. | Revised Up |
| Free cash flow growth | 8% to 10% growth | Dec 2025 | We continue to expect to grow free cash flow 9% to 11%. | On Track |
The full ledger
Open Zimmer Biomet Holdings’s full ledger
A free account opens 5 company ledgers a month. All 79 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 79 tracked commitments for Zimmer Biomet Holdings
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.